Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
2. Age≥18 years old, and≤70 years old ;
3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;
4. Patients with first-line treatment failure ;
5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ;
6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ;
7. The following three screening indicators should be met in the test screening period:

（1）The available tumor tissue samples ( paraffin sections and fresh surgical specimens ) were used for subsequent whole exome and transcriptome sequencing analysis and primary cell culture to obtain tumor neoantigen-related mutation sequence information and gene expression.

( 2 ) Available peripheral blood samples; ( 3 ) Tumor new antigen prediction analysis and in vitro laboratory testing; 8. ECOG score 0-1 ( see Appendix ) and expected survival time greater than 6 months ; 9. Patients were not allowed to use anti-tumor drugs and radiotherapy within 4 weeks before vaccination; 10. Patients with brain metastasis who were stable for at least one month after treatment can be included; 11. echocardiography showed left ventricular ejection fraction ≥ 50 %; 12. The results of laboratory tests should meet at least the following indicators :

1. White blood cell count ≥ 3.0 × 109 / L;
2. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
3. absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 / L;
4. platelet ( PLT ) ≥ 75 × 109 / L;
5. hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
6. Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
7. partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
8. serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
9. Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
10. Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
11. total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.

Exclusion Criteria:

* 1\. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.

  2\. Age≥18 years old, and≤70 years old ; 3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ; 4. Patients with first-line treatment failure ; 5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ; 6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ; 7. The following three screening indicators should be met in the test screening period:

  （1）The available tumor tissue samples ( paraffin sections and fresh surgical specimens ) were used for subsequent whole exome and transcriptome sequencing analysis and primary cell culture to obtain tumor neoantigen-related mutation sequence information and gene expression.

( 2 ) Available peripheral blood samples; ( 3 ) Tumor new antigen prediction analysis and in vitro laboratory testing; 8. ECOG score 0-1 ( see Appendix ) and expected survival time greater than 6 months ; 9. Patients were not allowed to use anti-tumor drugs and radiotherapy within 4 weeks before vaccination; 10. Patients with brain metastasis who were stable for at least one month after treatment can be included; 11. echocardiography showed left ventricular ejection fraction ≥ 50 %; 12. The results of laboratory tests should meet at least the following indicators :

1. White blood cell count ≥ 3.0 × 109 / L;
2. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
3. absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 / L;
4. platelet ( PLT ) ≥ 75 × 109 / L;
5. hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
6. Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
7. partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
8. serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
9. Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
10. Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
11. total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.